CETUXIMAB |
CMAB009 |
MOAB C225 |
CETUXIMAB (GENETICAL RECOMBINATION) |
ABP-494 |
IMC-225 |
C225 |
ERBITUX |
CMAB-009 |
C-225 |
IMC-C225 |
ANTI EGFR |
rxcui:318341 |
chemidplus:205923-56-4 |
chembl:CHEMBL1201577 |
drugbank:00002 |
FDA Approval | Colorectal cancer (KRAS wild type), Squamous cell carcinoma of the head and neck |
Drug Class | Therapeutic Antibodies |
Year of Approval | 2004 |
Drug Class | antineoplastic agents |
Pharmaceutical Developer | Bristol-Myers Squibb |
Source Reported Drug Name(s) | Cetuximab |
Drug Class | Monoclonal Antibody |
FDA Approval | approved |
Drug Indications | antineoplastic agent |
n/a |
combination therapy | Cetuximab + PLX4720 |
combination therapy | Vemurafenib + Cetuximab |
combination therapy | Cetuximab + Dabrafenib + SCH772984 |
antibody (inhibitory) |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Notes | |
Mechanism of Interaction | Epidermal growth factor receptor erbB1 inhibitor |
Direct Interaction | yes |
n/a |
Clinical Status | late trials |
Pathway | activation |
Variant Effect | gain-of-function |
n/a |
IMC-C225 | Development Name |
CETUXIMAB | Generic Name |
ERBITUX | Trade Name |
Drug Class | Therapeutic Antibodies |
FDA Approval | Colorectal cancer (KRAS wild type), Squamous cell carcinoma of the head and neck |
CETUXIMAB | Primary Drug Name |
Drug Class | antineoplastic agents |
Year of Approval | 2004 |
IFL Protocol | PubChem Drug Name |
56842117 | PubChem Drug ID |
Erbitux | Drug Trade Name |
Drug Class | Monoclonal Antibody |
Source Reported Drug Name(s) | Cetuximab |
Pharmaceutical Developer | Bristol-Myers Squibb |
Drug Indications | antineoplastic agent |
Drug Class | monoclonal antibody |
FDA Approval | approved |
C1723 | NCI drug code |
C225 | NCI drug code |
C1723 | NCI drug code |
C225 | NCI drug code |
CETUXIMAB | Primary Drug Name |
CETUXIMAB | Drug Generic Name |
ERBITUX | Drug Trade Name |
D0N5OV | TTD Drug ID |